Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 11 Jun 2021
PHARMAC’s decision over diabetes drugs could see up to 140,000 ‘miss out’, doctor says
11 June 2021 - Dr John Baker, the chair of the Diabetes Foundation Aotearoa, says that has to change and highlights ...
Posted by Michael Wonder on 10 Jun 2021
Biogen’s new Alzheimer’s drug could cost Medicare billions of dollars a year, report finds
10 June 2021 - “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s ...
Posted by Michael Wonder on 10 Jun 2021
America’s approval of an Alzheimer’s drug is premature
12 June 2021 - It may offer false hope and divert resources from more promising therapies. ...
Posted by Michael Wonder on 10 Jun 2021
Health Canada grants interim order authorisation for casirivimab and imdevimab for the treatment of mild to moderate COVID-19
10 June 2021 - Interim data shows treatment with casirivimab and imdevimab resulted in a statistically significant reduction in viral ...
Posted by Michael Wonder on 10 Jun 2021
FDA accepts filing of abbreviated new drug application and grants priority review for nalmefene hydrochloride injection for the treatment of known or suspected opioid overdose
10 June 2021 - Purdue Pharma announced that FDA has accepted and granted priority review to the company’s abbreviated new ...
Posted by Michael Wonder on 10 Jun 2021
Core patient reported outcomes in cancer clinical trials
9 June 2021 - This guidance provides recommendations to sponsors for collection of a core set of patient reported clinical outcomes ...
Posted by Michael Wonder on 10 Jun 2021
Yuhan's Leclaza to be cheaper than AstraZeneca's Tagrisso
10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...
Posted by Michael Wonder on 10 Jun 2021
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...
Posted by Michael Wonder on 10 Jun 2021
COVID-19 vaccine weekly safety report (10 June 2021)
10 June 2021 - Seven additional cases of blood clots with low blood platelets have been assessed as thrombosis with ...
Posted by Michael Wonder on 10 Jun 2021
ATAGI update following weekly COVID-19 meeting – 9 June 2021
10 June 2021 - An update from the Australian Technical Advisory Group on Immunisation following their weekly meeting on 9 June ...
Posted by Michael Wonder on 10 Jun 2021
Adamis provides update on Zimhi
9 June 2021 - FDA deems new drug application for Zimhi complete and establishes a target action date of 12 November ...
Posted by Michael Wonder on 10 Jun 2021
CyMedica Orthopedics announces FDA clearance for IntelliHab, a novel drug free, non-invasive modality for treatment of knee osteoarthritis pain
9 June 2021 - CyMedica Orthopedics today announced the U.S. FDA has cleared the submission of its latest technology for ...
Posted by Michael Wonder on 10 Jun 2021
Copiktra (duvelisib) receives European Union marketing authorisation for the treatment of relapsed or refractory CLL and refractory FL
9 June 2021 - Secura Bio today announced that on 19 May 2021, the European Medicines Agency granted marketing authorisation for ...
Posted by Michael Wonder on 10 Jun 2021
Two members of U.S. FDA advisory panel resign over Alzheimer's drug approval
9 June 2021 - Two members of a panel of outside advisors to the U.S. FDA have resigned in protest ...